SV2009003227A - Composiciones de inhibidores de chk 1 ref. x-17672 - Google Patents
Composiciones de inhibidores de chk 1 ref. x-17672Info
- Publication number
- SV2009003227A SV2009003227A SV2009003227A SV2009003227A SV2009003227A SV 2009003227 A SV2009003227 A SV 2009003227A SV 2009003227 A SV2009003227 A SV 2009003227A SV 2009003227 A SV2009003227 A SV 2009003227A SV 2009003227 A SV2009003227 A SV 2009003227A
- Authority
- SV
- El Salvador
- Prior art keywords
- chk
- compositions ref
- inhibitors compositions
- inhibitors
- ref
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSICIONES QUE CONTIENEN AL MENOS, UN INHIBIDOR DE CHKL Y AL MENOS UNA CICLODEXTRINA. TAMBIÉN SE DESCRIBEN MÉTODOS PARA TRATAR UN CÁNCER O POTENCIAR UN TRATAMIENTO DE CÁNCER CON UNA COMPOSICIÓN QUE COMPRENDE AL MENOS, UN INHIBIDOR DE CHKL Y AL MENOS UNA CICLODEXTRINA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85305606P | 2006-10-20 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2009003227A true SV2009003227A (es) | 2010-02-04 |
Family
ID=39338658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2009003227A SV2009003227A (es) | 2006-10-20 | 2009-04-20 | Composiciones de inhibidores de chk 1 ref. x-17672 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8455471B2 (es) |
EP (1) | EP2063879A2 (es) |
JP (1) | JP2010506942A (es) |
KR (2) | KR20090065537A (es) |
CN (1) | CN101528215B (es) |
AU (1) | AU2007325576B2 (es) |
BR (1) | BRPI0717460A2 (es) |
CA (1) | CA2673483C (es) |
CO (1) | CO6180503A2 (es) |
CR (1) | CR10680A (es) |
EA (1) | EA200900571A1 (es) |
IL (1) | IL197869A (es) |
MA (1) | MA30872B1 (es) |
MX (1) | MX2009004214A (es) |
MY (1) | MY150649A (es) |
NO (1) | NO20091544L (es) |
NZ (1) | NZ575394A (es) |
SV (1) | SV2009003227A (es) |
TN (1) | TN2009000146A1 (es) |
UA (1) | UA95310C2 (es) |
WO (1) | WO2008067027A2 (es) |
ZA (1) | ZA200902670B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA022890B1 (ru) | 2009-05-29 | 2016-03-31 | Сидекс Фармасьютикалз, Инк. | Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
KR20140078619A (ko) * | 2011-09-18 | 2014-06-25 | 유로-셀띠끄 소시에떼 아노님 | 약학적 조성물 |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
PT2763984T (pt) | 2011-10-03 | 2016-07-25 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38 |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
CA2870316C (en) * | 2012-04-13 | 2022-04-19 | L&F Health Llc | Hydroxypropyl beta cyclodextrin in the treatment of a proteinuric glomerural disease |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
JP6630280B2 (ja) | 2014-02-14 | 2020-01-15 | レスピバート・リミテツド | 抗炎症化合物としての芳香族複素環化合物 |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US9890564B2 (en) * | 2014-10-28 | 2018-02-13 | Sargent Manufacturing Company | Interconnected lock with direct drive for adjustable deadbolt to latchbolt spacing |
JP2017155023A (ja) * | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Lat1阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤 |
EP3432880A4 (en) * | 2016-03-20 | 2019-12-11 | Asdera LLC | USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNANT AND NEURODEGENERATIVE DISORDERS |
AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
EP3687549A4 (en) | 2017-09-28 | 2021-07-14 | Asdera LLC | USE OF CYCLODEXTRIN IN DISEASES AND DISORDERS WITH PHOSPHOLIPID FAILURE REGULATION |
CN109078005B (zh) * | 2018-08-07 | 2021-11-26 | 江苏领航生物科技有限公司 | 一种白消安组合物及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
HU193933B (en) * | 1984-06-08 | 1987-12-28 | Nitrokemia Ipartelepek | Herbicide or plant growth stimulating agent comprising beta-cyclodextrin complex of benzolsulphonylurea derivative and process for preparing the active substances |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
AU759280C (en) * | 1998-02-23 | 2004-01-22 | Cyclops, Ehf | High-energy cyclodextrin complexes |
MXPA02012909A (es) | 2000-07-24 | 2004-05-05 | Boehringer Ingelheim Pharma | Formulaciones mejoradas de dosis oral de 1-(5-ter-butil -2-p-tiolil2h -pirazol-3 -il)-3-(4-2 (2-morfolin-4-il -etoxi) -naftalen -1-il) -urea. |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
WO2003015828A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin |
SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
CN1882342A (zh) * | 2003-09-17 | 2006-12-20 | 艾科斯有限公司 | Chk1抑制剂在控制细胞增殖中的应用 |
KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
NZ561458A (en) * | 2005-03-29 | 2011-03-31 | Icos Corp | Heteroaryl urea derivatives useful for inhibiting CHK1 |
CN1813739A (zh) | 2005-11-25 | 2006-08-09 | 王颖 | 一种注射用盐酸纳美芬冻干粉针制剂 |
-
2007
- 2007-10-02 CN CN2007800390301A patent/CN101528215B/zh not_active Expired - Fee Related
- 2007-10-02 EP EP07871106A patent/EP2063879A2/en not_active Withdrawn
- 2007-10-02 AU AU2007325576A patent/AU2007325576B2/en not_active Ceased
- 2007-10-02 KR KR1020097007975A patent/KR20090065537A/ko not_active Application Discontinuation
- 2007-10-02 WO PCT/US2007/080150 patent/WO2008067027A2/en active Application Filing
- 2007-10-02 US US12/442,529 patent/US8455471B2/en not_active Expired - Fee Related
- 2007-10-02 JP JP2009533425A patent/JP2010506942A/ja active Pending
- 2007-10-02 EA EA200900571A patent/EA200900571A1/ru unknown
- 2007-10-02 NZ NZ575394A patent/NZ575394A/en not_active IP Right Cessation
- 2007-10-02 MY MYPI20091558 patent/MY150649A/en unknown
- 2007-10-02 UA UAA200903745A patent/UA95310C2/ru unknown
- 2007-10-02 BR BRPI0717460-8A2A patent/BRPI0717460A2/pt not_active IP Right Cessation
- 2007-10-02 MX MX2009004214A patent/MX2009004214A/es active IP Right Grant
- 2007-10-02 KR KR1020117017995A patent/KR20110098009A/ko not_active Application Discontinuation
- 2007-10-02 CA CA2673483A patent/CA2673483C/en not_active Expired - Fee Related
-
2009
- 2009-03-20 CR CR10680A patent/CR10680A/es unknown
- 2009-03-26 IL IL197869A patent/IL197869A/en not_active IP Right Cessation
- 2009-04-17 CO CO09039148A patent/CO6180503A2/es not_active Application Discontinuation
- 2009-04-17 ZA ZA200902670A patent/ZA200902670B/xx unknown
- 2009-04-17 TN TNP2009000146A patent/TN2009000146A1/fr unknown
- 2009-04-20 NO NO20091544A patent/NO20091544L/no not_active Application Discontinuation
- 2009-04-20 SV SV2009003227A patent/SV2009003227A/es unknown
- 2009-05-07 MA MA31850A patent/MA30872B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010506942A (ja) | 2010-03-04 |
CO6180503A2 (es) | 2010-07-19 |
IL197869A (en) | 2013-11-28 |
US8455471B2 (en) | 2013-06-04 |
WO2008067027A2 (en) | 2008-06-05 |
NO20091544L (no) | 2009-06-10 |
CN101528215A (zh) | 2009-09-09 |
IL197869A0 (en) | 2009-12-24 |
EP2063879A2 (en) | 2009-06-03 |
MY150649A (en) | 2014-02-14 |
UA95310C2 (ru) | 2011-07-25 |
MA30872B1 (fr) | 2009-11-02 |
NZ575394A (en) | 2012-01-12 |
CR10680A (es) | 2009-10-13 |
KR20110098009A (ko) | 2011-08-31 |
AU2007325576A1 (en) | 2008-06-05 |
CA2673483C (en) | 2014-04-08 |
KR20090065537A (ko) | 2009-06-22 |
CN101528215B (zh) | 2011-10-19 |
ZA200902670B (en) | 2010-06-30 |
CA2673483A1 (en) | 2008-06-05 |
EA200900571A1 (ru) | 2009-12-30 |
US20100022512A1 (en) | 2010-01-28 |
WO2008067027A3 (en) | 2009-04-16 |
BRPI0717460A2 (pt) | 2013-12-24 |
TN2009000146A1 (en) | 2010-10-18 |
MX2009004214A (es) | 2009-05-11 |
AU2007325576B2 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2009003227A (es) | Composiciones de inhibidores de chk 1 ref. x-17672 | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
CO6331446A2 (es) | Composiciones farmaceúticas que comprenden la combinación de un agente antimitotico y un compuesto inhibidor de aurora quinasa, utiles en el tratamiento anticancerígeno | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
CR20140544A (es) | Compuestos para inhibir la progresión mitotica | |
NI200700320A (es) | Inhibidores de la actividad akt | |
MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
HN2009001112A (es) | Inhibidores de la actividad de la akt | |
NO20081636L (no) | FAP - inhibitorer | |
BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
MX2009005795A (es) | Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona. | |
WO2007059154A3 (en) | Treatment of cancers with acquired resistance to kit inhibitors | |
ES2571730T3 (es) | Composiciones farmacéuticas que comprenden droxidopa | |
ECSP056011A (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
BRPI0603772A (pt) | composições para a inibição ou redução de inflamação da pele | |
WO2008033807A3 (en) | Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer |